Woburn, MA, April 10, 2024 — Fuse Biotherapeutics, Inc., a biotechnology company developing functionally-selective cytokines for cancer and autoimmune disease, today announced the presentation of new data with respect to their lead asset PD1-F18, at the American Association for Cancer Research (AACR) Annual Meeting being held on April 5-10, 2024, in San Diego, CA. The Fuse Biotherapeutics team will present data on April 9, 2024…